• Prof. Dr. Martin Zörnig

    Tel.: +49 69 63395-115



    Malz M, Bovet M, Samarin J, Rabenhorst U, Sticht C, Bissinger M, Roessler S, Lorenzo Bermejo J, Renner M, Calvisi DF, Singer S, Ganzinger M, Weber A, Gretz N, Zörnig M, Schirmacher P, Breuhahn K.
    Overexpression of far upstream element (FUSE) binding protien (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma.
    Hepatology. 2014 May 13. doi: 10.1002/hep.27218. [Epub ahead of print]

    Michalik KM, You X, Manavski Y, Doddaballapur A, Zörnig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, Boon RA, Dimmeler S.
    Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth.
    Circ Res. 2014 Apr 25;114(9):1389-97.

    Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, Bermejo JL, Radlwimmmer B, Zörnig M, Zender L, Dombrowski F, Evert M, Schirmacher P, Longerich T.
    EEF1A2 inactivates p53 via PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.
    Hepatology 2014 May;59(5):1886-99.

    Baumgarten P, Harter PN, Tönjes M, Capper D, Blank A-E, Sahm F, von Deinling A, Kolluru K, Schwamb B, Rabenhorst U, Starzetz T, Kögel D, Rieker RJ, Plate KH, Ohgaki H, Radlwimmer B, Zörnig M1, Mittelbronn M1.
    Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.
    1 both senior authors contributed equally to the work
    Neuropathol Appl Neurobiol. 2014 Feb;40(2):205-16.



    Eißmann M, Schwamb B, Melzer I, Moser J, Köhl U, Rieker RJ, Wachter DL, Agaimy A, Herpel E, Rakel S, Kögel D, Böhm S, Gutschner T, Diederichs S, Zörnig M.
    A functional yeast survival screen of tumor-derived cDNA libraries designed to identify anti-apoptotic mammalian oncogenes.
    PLoS One. 2013 May 22;8(5):e64873.

    Gutschner T, Hämmerle M, Eißmann M, Hsu J, Kim Y, Hung G, Revenko AS, Arun G, Stentrup M, Groß M, Zörnig M, Macleod AR, Spector DL, Diederichs S.
    The non-coding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells.
    Cancer Res. 2013 Feb 1;73(3):1180-9.

    Eißmann M, Melzer IM, Mateus Fernández SB, Michel G, Hrab? de Angelis M, Hoefler G, Finkenwirth P, Jauch A, Schoell B, Grez M, Schmidt M, Bartholomae CC, Newrzela S, Haetscher N, Rieger MA, Zachskorn C, Mittelbronn M, Zörnig, M.
    Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms.
    Oncogene 2013 May 16:32(20):2586-91.



    Heide H, Bleier L, Steger M, Ackermann J, Dröse S, Schwamb B, Zörnig M, Reichert AS, Koch I, Wittig I, Brandt U.
    Complexome profiling identifies TMEM126B as a component of the mitochondrial complex I assembly (MCIA) complex.
    Cell Metab. 2012 Oct3;16(4):538-49.

    Eißmann M, Gutschner T, Hämmerle M, Günther S, Caudron-Herger M, Groß M, Schirmacher P, Rippe K, Braun T, Zörnig M1, Diederichs S1.
    Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development.
    1 both senior authors contributed equally to the work
    RNA Biol. 2012 Aug;9(8):1076-87.

    Tscheliessnig R, Zörnig M, Herzig EM, Lückerath K, Altrichter J, Kemter K, Paunel-Görgülü A, Lögters T, Windolf J, Pabisch S, Cinatl J, Rabenau HF, Jungbauer A, Müller-Buschbaum P, Scholz M, Koch, J.
    Nano-coating protects biofunctional materials.
    Materials Today 2012; 15: 394-404.

    Melzer IM, Mateus Fernández SB, Bösser S, Lohrig K, Lewandrowski U, Wolters D, Kehrloesser S, Brezniceanu ML, Theos AC, Irusta PM, Impens F, Gevaert K, Zörnig M.
    The Apaf-1-binding protein Aven is cleaved by Cathepsin D to unleash its anti-apoptotic potential.
    Cell Death Differ. 2012 Sep;19(9):1435-45.



    Lückerath K, Kirkin V, Melzer IM, Thalheimer FB, Siele D, Milani W, Adler T, Aguilar-Pimentel A, Horsch M, Michel G, Beckers J, Busch DH, Ollert M, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Staal FJ, Rajalingam K, Hueber AO, Strobl LJ, Zimber-Strobl U, Zörnig M.
    Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain.
    Blood. 2011 Jan 13;117(2):519-29.



    Guardiola-Serrano F, Rossin A, Cahuzac N, Lückerath K, Melzer I, Mailfert S, Marguet D, Zörnig M, Hueber AO.
    Palmitoylation of human FasL modulates its cell death-inducing function.
    Cell Death Dis. 2010 Oct 21;1:e88.



    Paunel-Görgülü, A., Zörnig, M., Lögters, T., Altrichter, J, Rabenhorst, U., Cinatl, J., Windolf, J., and Scholz, M.
    Mcl-1-mediated impairment of the intrinsic apoptosis pathway in circulating neutrophils from critically ill patients can be overcome by Fas stimulation.
    J Immunol. 2009, 183, 6198-206.

    Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J, Chung HJ, Levens DL, Zörnig M.
    Overexpression of the Far Upstream Element Binding Protein FBP1 in hepatocellular carcinoma is required for tumor growth.
    Hepatology. 2009 Oct;50(4):1121-9



    Kirkin V, Cahuzac N, Guardiola-Serrano F, Huault S, Lückerath K, Friedmann E, Novac N, Wels WS, Martoglio B, Hueber AO, Zörnig M.
    The FasL intracellular domain is released by ADAM10 and SPPL2a cleavage in T cells.
    Cell Death and Differ. 2007, 14: 1678 - 87.

    Peter ME, Budd RC, Desbarats J, Hed-rick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zörnig M, Lynch DH.
    The CD95 receptor: Apoptosis revisited.
    Cell 2007, 129: 447 - 50.

    Wichmann C, Chen L, Heinrich M, Baus D, Pfitzner E, Zörnig M, Ottmann OG, Grez M.
    Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
    Cancer Res. 2007, 67(5):2280-9.



    Pick R, Badura S, Bösser S, Zörnig M.
    Upon intracellular processing, the C-terminal death domain-containing fragment of the p53-inducible PIDD/LRDD protein translocates to the nucleoli and interacts with nucleolin.
    Biochem Biophys Res Commun. 2006, 349(4):1329-38.

    Qian J, Chen W, Lettau M, Podda G, Zörnig M, Kabelitz D, Janssen O.
    Regulation of FasL expression: a SH3 domain containing protein family involved in the lysosomal association of FasL.
    Cell Signal. 2006, 18(8):1327-37.

    Cahuzac N, Baum W, Kirkin V, Con-chonaud F, Wawrezinieck L, Marguet D, Janssen O, Zörnig M1, Hueber AO1.
    Fas Ligand is localized to membrane rafts where it displays increased apoptosis-inducing activity.
    Blood 2006, 107: 2384 - 91.1, Both senior authors contributed equally to the work.

    Michaelis M, Suhan T, Michaelis UR, Beek K, Rothweiler F, Tausch L, Werz O, Eikel D, Zörnig M, Nau H, Fleming I, Doerr HW, Cinatl J Jr.
    Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells.
    Cell Death Differ. 2006, 13(3):446-53.

    Völp K, Brezniceanu ML, Bösser S, Brabletz T, Kirchner T, Göttel D, Joos S, Zörnig M.
    Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas.
    Gut. 2006, 55(2):234-42.

    Oehme I, Bösser S, Zörnig M.
    Agonists of an ecdysone-inducible mammalian expression system inhibit Fas Ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO.
    Cell Death Differ. 2006, 13(2):189-201.



    Baum W, Kirkin V, Mateus Fernández SB, Pick R, Lettau M, Janssen O, Zörnig M.
    Binding of the intracellular Fas Ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localiza-tion of FasL.
    JBC 2005, 280: 40012 - 24.

    Oehme I, Neumann F, Bösser S, Zörnig M.
    Transgenic overexpression of the Caspase-8 inhibitor FLIP(short) leads to impaired T cell proliferation and an increased memory T cell pool after staphylococcal enterotoxin B injection.
    Eur J Immunol. 2005, 35(4):1240-9.



    Hueber AO, Bösser S, Zörnig M.
    Transgenic overexpression of a dominant negative mutant of FADD that, although counterselected during tumor progression, cooperates in L-myc-induced tumorigenesis.
    Int J Cancer. 2004, 112(3):536-40.
    Kirkin V, Joos S, Zörnig M.
    The role of Bcl-2 family members in tumorigenesis.
    Biochim Biophys Acta. 2004, 1644(2-3):229-49.



    Brezniceanu ML, Völp K, Bösser S, Solbach C, Lichter P, Joos S, Zörnig M.
    HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma.
    FASEB J. 2003, 17: 1295 - 7.



    Zörnig M, Hueber A, Baum W, Evan G.
    Apoptosis regulators and their role in tumorigenesis.
    Biochim Biophys Acta. 2001, 1551(2):F1-37.



    Hueber AO, Zörnig M, Bernard AM, Chautan M, Evan G.
    A dominant negative Fas-associated death domain protein mutant inhibits proliferation and leads to impaired calcium mobilization in both T-cells and fibroblasts.
    J Biol Chem. 2000, 275(14):10453-62.



    Rödel B, Wagner T, Zörnig M, Niessing J, Möröy T.
    The human homologue (GFI1B) of the chicken GFI gene maps to chromosome 9q34.13-A locus frequently altered in hematopoietic diseases.
    Genomics. 1998, 54(3):580-2.
    Zörnig M, Hueber AO, Evan G.
    p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice.
    Curr Biol. 1998, 8(8):467-70.



    Hueber AO, Zörnig M, Lyon D, Suda T, Nagata S, Evan GI.
    Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis.
    Science 1997, 278: 1305 - 9.
    Ink B, Zörnig M, Baum B, Hajibagheri N, James C, Chittenden T, Evan G.
    Human Bak induces cell death in Schizosaccharomyces pombe with morphological changes similar to those with apoptosis in mammalian cells.
    Mol Cell Biol. 1997, 17(5):2468-74.



    Zörnig M, Evan GI.
    Cell cycle: on target with Myc.
    Curr Biol. 1996, 6(12):1553-6.
    Schmidt T, Zörnig M, Beneke R, Möröy T.
    MoMuLV proviral integrations identified by Sup-F selection in tumors from infected myc/pim bitransgenic mice correlate with activation of the gfi-1 gene.
    Nucleic Acids Res. 1996, 24(13):2528-34.
    Zörnig M, Schmidt T, Karsunky H, Grzeschiczek A, Möröy T.
    Zinc finger protein GFI-1 cooperates with myc and pim-1 in T-cell lymphomagenesis by reducing the requirements for IL-2.
    Oncogene. 1996, 12(8):1789-801.



    Zörnig M, Busch G, Beneke R, Gulbins E, Lang F, Ma A, Korsmeyer S, Möröy T.
    Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
    Oncogene. 1995, 11(10):2165-74.
    Zörnig M, Grzeschiczek A, Kowalski MB, Hartmann KU, Möröy T.
    Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV.
    Oncogene. 1995, 10(12):2397-401.
    Zörnig M, Klett C, Lovec H, Hameister H, Winking H, Adolph S, Möröy T.
    Establishment of permanent wild-mouse cell lines with readily identifiable marker chromosomes.
    Cytogenet Cell Genet. 1995, 71(1):37-40.



    Theil T, McLean-Hunter S, Zörnig M, Möröy T.
    Mouse Brn-3 family of POU transcription factors: a new aminoterminal domain is crucial for the oncogenic activity of Brn-3a.
    Nucleic Acids Res. 1993, 21(25):5921-9.



    Grez M, Zörnig M, Nowock J, Ziegler M.
    A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells.
    J Virol. 1991, 65(9):4691-8.


    - To Top of the Page -